News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


MSNZ welcomes consultation period for Tysabri and Gilenya

Media release (8 August 2014)


MSNZ welcomes beginning of consultation period for Tysabri and Gilenya as proposed new first-line treatments for relapsing remitting forms of Multiple Sclerosis.

The Multiple Sclerosis Society of New Zealand (MSNZ) welcomes PHARMAC’s release of a consultation document today that proposes Natalizumab (Tysabri)and Fingolimod (Gilenya) as potential new first-line treatments for relapsing, remitting forms of MS.

PHARMAC is seeking feedback on a funding proposal involving five treatments for multiple sclerosis (MS), including these two new treatments. It is also seeking feedback on potential changes to the currently funded treatments Avonex, Betaferon and Copaxone.

In February, PTAC (the Pharmaceutical Technical Advisory Committee) recommended to PHARMAC that these new treatments be funded as new first-line treatments.

“It has been a long process to get to this point but PHARMAC’s announcement is a positive step,” says MSNZ spokesman Neil Woodhams. “Relapsing Remitting MS is one of four types of MS, affecting the highest percentage of patients. These new treatments, if accepted by PHARMAC, will be given as soon after diagnosis as possible, to patients fitting within the criteria. This is a great start for all those who will benefit from these treatments.”

Subject to a positive outcome from its consultation process, PHARMAC has suggested that Natalizumab and Fingolimod could be listed on the Hospital Medications List by 1 November 2014 and that changes to the restrictions around access to treatments that are currently funded could also be made by that date.

“This is not the end of the process,” says Mr Woodhams. “The next stage of consultation begins today. We recommend that interested parties read the consultation documents carefully as there are restrictions on the access to these treatments and changes that will be made to the currently-funded treatments.”

Submissions on PHARMAC’s consultation document close on 29 August, 2014.

“MSNZ would like to thank everyone involved in the Patients’ Steering Group, the MS Community, neurologists and supporters who have helped to highlight the importance of funding these new first-line treatments. MSNZ has been overwhelmed with the support and commitment shown to date and we urge supporters to maintain their level of engagement during the next stage of the process and beyond.”


More information about the consultation documents:
For more information visit the PHARMAC website:
www.pharmac.health.nz/news/consultation-2014-08-07-mstreatments/

Details of the proposal, including proposed funding access criteria, and some background information can be found at:
www.pharmac.health.nz/assets/consultation-2014-08-07-mstreatments.pdf

Please note: The fingolimod component of this proposal is dependent on a multi-product provisional agreement with Novartis, for a number of other products including fingolimod, being approved. PHARMAC are consulting on the Novartis multiproduct proposal separately, see PHARMAC’s website at: www.pharmac.health.nz/news/consultation-2014-08-07-multiproduct.
www.pharmac.health.nz/assets/consultation-2014-08-07-multiproduct.pdf

About MSNZ:
For more information about MSNZ please email info@msnz.org.nz or call 0800 MS LINE (67 54 63).

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Howard Davis Review: Dick Frizzell At The Solander Gallery

One of the most influential and celebrated contemporary Pop artists working in New Zealand, Dick Frizzell is mostly known for his appropriation of kitsch Kiwiana icons, which he often incorporates into cartoon-like paintings and lithographs. Not content with adhering to one particular style, he likes to adopt consciously unfashionable styles of painting, in a manner reminiscent of Roy Lichtenstein. More>>

Old Music: Pop Icon Adam Ant Announces NZ Tour

Following his recent sold out North American and UK tours, Adam Ant is celebrating the 35th anniversary of the release of his landmark KINGS OF THE WILD FRONTIER album with a newly-remastered reissue (Sony Legacy) and Australasian tour. More>>

Scoop Review Of Books:
Looking Back

Writing a memoir that appeals to a broad readership is a difficult undertaking. As an experienced communicator, Lloyd Geering keeps the reader’s interest alive through ten chapters (or portholes) giving views of different aspects of his life in 20th-century New Zealand. More>>

Scoop Review Of Books: Purple (and Violet) Prose

This is the second recent conjoint publication by Reeve and Stapp; all to do with esoteric, arcane and obscure vocabulary – sesquipedalian, anyone – and so much more besides. Before I write further, I must stress that the book is an equal partnership between words and images and that one cannot thrive without the other. More>>

Howard Davis: Get It On, Bang A Gong, Pt I

Several readers have recently inquired about the significance of the image that accompanies my by-line. While the man-bun is long gone, I still incorporate the sound of the gong in my Kundalini Yoga classes. More>>

ALSO:

Breaking The Ice: U.S. Antarctic Icebreaker Visits New Zealand

The United States has sought, and been granted, New Zealand’s permission for a U.S. Coast Guard icebreaker, the U.S. Coast Guard Cutter (USCGC) POLAR STAR (WAGB-10), to make a port call at Lyttelton on its way home from Antarctica sometime later this month. More>>

Scoop Review Of Books: Trading Places

Greg Clydesdale, a lecturer in business at Lincoln University, has written a comprehensive account of global trade from the seventh century to modern times. More>>

Sheep: Shearing Record Smashed In Hawke’s Bay

Three shearers gathered from around New Zealand have smashed a World record by 264 sheep despite the heat, the pumiced sheep of inland Hawke’s Bay and a year’s wool weighing an average of over 3.5kg a sheep. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news